ArticleFrontiers in immunology2026
Rituximab is associated with accelerated dialysis independence in anti-glomerular basement membrane disease: a retrospective cohort analysis of renal survival.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the efficacy of rituximab (RTX) in the treatment of anti-glomerular basement membrane disease (anti-GBM disease) and to analyze the clinicopathological factors associated with long-term renal outcomes. Methods: This study enrolled a total of 66 patients with confirmed anti-GBM disease. Patients were divided into two groups: the control group (n=52) received conventional therapy, including plasma exchange, glucocorticoids, and cyclophosphamide as clinically indicated, and the RTX group (n=14) received RTX in addition to the same conventional therapy. The baseline characteristics, treatment responses, and long-term outcomes were compared between the two groups. Results: The baseline clinical and pathological characteristics were balanced and comparable between the two groups. Although the RTX group demonstrated only numerical advantages in the absolute rate of dialysis independence (50.0% vs. 21.05%, p=0.107) and the 3-year ESRD incidence (42.86% vs. 63.46%, p=0.223), the median time to dialysis independence was significantly shorter in the RTX group compared to the control group (26 vs. 41 days, p=0.009). Kaplan-Meier survival analysis indicated a trend towards higher renal survival in the RTX group, but the difference was not statistically significant (HR = 0.640, p=0.169). Prognostic factor analysis indicated that worse baseline renal function, anemia, hypoalbuminemia, elevated BNP, initial dialysis dependency, and absence of cyclophosphamide treatment were associated with progression to ESRD at 3 years. Conclusion: In patients with anti-GBM disease, the addition of RTX to standard therapy was associated with accelerated recovery of renal function, as evidenced by a shorter time to dialysis discontinuation. These findings suggest a potential renal recovery benefit of RTX, warranting further validation in larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.